Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma

Video

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist and oncologist, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel (ide-cel; bb2121) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma.

It is possible that the myeloma armamentarium will gain 2 CAR T-cell therapies in the near future, says Shah. However, selecting between the therapies if both receive FDA approval could be challenging, Shah adds.

Without comparing trials, subtle differences between ide-cel and cilta-cel have been observed, says Shah. Findings from the phase 2 KarMMA trial demonstrated a 73% overall response rate (ORR) with ide-cel, whereas the results of the phase 1/2 CARTITUDE-1 trial demonstrated an ORR of 96.9% with cilta-cel. Both products appear to induce deep and durable responses, but additional follow-up with cilta-cel is needed, says Shah.

Additionally, the median onset of cytokine release syndrome (CRS) was 2 days with ide-cel compared with 7 days with cilta-cel, which makes the latter more unpredictable in terms of toxicity management, Shah explains. As such, some patients may be better suited for ide-cel vs cilta-cel, but more data are needed, concludes Shah.

Recent Videos
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
© 2025 MJH Life Sciences

All rights reserved.